Bringing the very best science and medicine to our best equine friends

NEWS

PRESS RELEASE – Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016. In the target animal safety study, Zimeta, was well tolerated with no clinically-significant changes when compared to control horses (placebo ...
Continue Reading

Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016. In the target animal safety study, Zimeta, was well tolerated with no clinically-significant changes when compared to control horses (placebo …

Continue Reading

Kindred Biosciences Announces Fourth Quarter and Year-End 2015 Financial Results

San Francisco, CA (March 2, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2015. “We are very pleased with the progress on Zimeta™, our lead product candidate, and look forward to our first product approval and launch,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are also pleased to report that the strong pipeline of additional products, including KIND-010 for management of weight in cats and feline epo for anemia in cats, are also …

Continue Reading

Kindred Biosciences to Announce Fourth Quarter and Year-End 2015 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 2, 2016 San Francisco, CA (February 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2015 financial results on March 2, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, …

Continue Reading

Kindred Biosciences Submits Zimeta (KIND-012) New Animal Drug Application Technical Section for Effectiveness to FDA

San Francisco, CA (February 11, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012). Positive topline results from the pivotal field study (KB0120) of Zimeta for the control of pyrexia (fever) in horses were recently reported by the Company. The Chemistry, Manufacturing, and Controls technical section for Zimeta was submitted in December 2015 and all remaining technical sections of the NADA are planned for submission by the end …

Continue Reading

Kindred Biosciences Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

Monday, January 11, 2016 Time of Event: 8:30 AM Eastern Standard Time Webcast URL: http://edge.media-server.com/m/p/sfos7gz9  For more information on this event, please see the press release

Continue Reading

Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.

Continue Reading